GSK shares dropped over 9% following a Delaware court decision allowing 70,000 lawsuits over discontinued heartburn drug Zantac, with the company planning to appeal.
GlaxoSmithKline (GSK) experienced a significant blow as its shares dropped over 9% due to a court decision in Delaware, U.S., allowing over 70,000 lawsuits to proceed against the pharmaceutical giant regarding the heartburn medication Zantec. This ruling wiped out most of the company's gains for the year, leading to a loss of over £6 billion in market value. The litigation concerns the claim that Zantac, a drug once manufactured by GSK, Pfizer, and Sanofi, may cause cancer. The Delaware Superior Court, under Judge Vivian Medinilla, decided that expert witnesses could testify that Zantac could potentially lead to cancer, citing a reluctance to interfere in the technical debate between opposing scientific viewpoints.
Despite this setback, Deutsche Bank maintained a "buy" rating on GSK, highlighting the company's long-term potential and setting a share price target offering a 21% premium over the current price. The investment bank acknowledged the challenges posed by the litigation but appeared optimistic about GBS’s ability to refocus on its core business and growth opportunities post-litigation.
The controversy around Zantac began after it was discovered that the drug could potentially produce NDMA, a probable human carcinogen, leading to its recall and discontinuation in European and U.S. markets between 2019 and 2020. The companies involved have been defending against claims that they failed to warn consumers about the cancer risk associated with Zantac. GSK, in response to the ruling, stated that it plans to appeal, emphasizing that the Delaware decision does not reflect an agreement with the plaintiffs' scientific conclusions nor does it determine liability. Similarly, Pfizer and Sanofi expressed their intentions to contest the decision, with Pfizer noting a prior settlement of a substantial number of cases where it was named as a defendant.
Adding to the complexity, the legal landscape saw a partial victory for GSK and Boehringer Ingelheim in Illinois, where a jury found the companies not liable for colorectal cancer in the first Zantac case to reach trial. Analysts speculate that GSK, being the most exposed to the lawsuits, could face settlement costs ranging from $1 billion to over $3 billion. This wave of litigation and the accompanying market response underscores the ongoing challenges pharmaceutical companies face when safety concerns emerge regarding their products.
Verizon's recent $20B acquisition of Frontier Communications offers growth opportunities but also increases risk, potentially impacting dividends and stock outlook.
Boeing's troubled Starliner spacecraft is set to return to Earth uncrewed on Friday evening after undocking from the International Space Station.
Qualcomm is exploring acquiring parts of Intel's design business to enhance its product portfolio.
Fed Governor Christopher Waller stated, 'Given the progress on reducing inflation and the moderation in the labor market, I think it's time to lower the federal funds rate at our next meeting.' His comments came after a weaker-than-expected nonfarm payrolls report on Friday, which reinforced the idea that hiring is slowing down.
Nvidia remains a dominant player in the AI chip market with impressive revenue growth, but faces recent stock decline, CEO share sales, and competition despite robust Q2 2025 earnings and long-term opportunities in data center GPUs and liquid cooling technology.
Stock markets remain volatile as investors await a crucial jobs report, with concerns about the U.S. economy and recession fears causing significant market swings.
The Dutch government is expanding export restrictions on ASML's advanced semiconductor equipment, requiring new licenses for two more DUV lithography tools, aligning with US sanctions against China.
Samsara Inc. (IOT) reported better-than-expected Q2 earnings, with revenue at $300.2 million and raised its FY25 guidance.
UiPath reported strong Q2 financial results with ARR growing 19% year-over-year, raised its fiscal 2025 revenue guidance, and approved a $500 million stock buyback program, but shares fell despite positive news.